TENX heads into the final week of July in an unusual position: short interest remains towering at over a quarter of the free float, yet the borrow market has never been looser, and shorts have been cutting exposure all week.
The most striking dynamic in the lending market is the sheer contradiction between scale and ease. Short interest is running at 27.1% of free float — roughly doubled from the ~13% reading in mid-June — making TENX one of the more heavily shorted small-cap biotech names on Nasdaq. Yet borrow availability is extraordinarily loose at 2,096%, meaning there are more than twenty shares available to lend for every one currently borrowed. That availability is actually rising, up ~51% week-on-week, and is miles above the 52-week tightest point of 23.75%. Cost to borrow has collapsed in parallel — down 35% over the past month to just 0.50% annualised, the lowest in that window. The message from the lending market is unambiguous: there is no squeeze pressure here. Shorts can enter and exit freely, and are doing so. Short interest fell ~15% on the week after peaking near 2 million shares on July 14, even as the overall level remains elevated.
The short score reinforces the same read. It pulled back to 41.8 from a peak of 46.1 on July 13–14, tracking the retreat in positioned shares — a signal that, in ORTEX's composite view, the aggressive short-side pressure of last week has cooled. Options are leaning modestly more cautious, with the put/call ratio at 0.29, slightly above its 20-day average of 0.21 and running a standard deviation above the norm. That's nudging toward defensive territory, but the PCR remains well below the 52-week high of 3.67 — so options positioning reflects mild hedging, not fear.
The stock itself has had a strong month, gaining 31% to close at $15.72, though it has been essentially flat on the week — up just 1% — while correlated biotech peers have been under pressure. BBIO fell nearly 2% on the week, TYRA dropped 3.1%, and AKBA shed 7.1%. TENX's relative resilience is notable given the size of the short book sitting against it. Fidelity (FMR LLC) emerged as the largest institutional holder with a 7.7% stake, reported as of June 30, having added 3.6 million shares in the most recent filing window. Perceptive Advisors, Stonepine Capital, and Logos Global also built new or near-full positions, per March filings — a cluster of specialist biotech money that tends to signal conviction on the clinical pipeline.
Valuation tells you this is a pre-profitability story. The PE ratio is negative at –11.3, the earnings yield deeply negative at –8.8 cents per dollar of equity, and there are no analyst forward estimates in the data. The next scheduled earnings event arrives August 13. Historical print reactions have been volatile: the March 25 event generated a 13% one-day rally and a 21% five-day gain, while the May 12 and May 15 events were flat-to-small-negative. The full range of one-day moves across the last four prints runs from –2.4% to +32.7% — a reminder that this stock moves on binary catalysts, not on guidance refinement.
With the August 13 earnings date approaching and shorts still holding a substantial 27% of the float despite partial retreat, the key question is whether the borrow market's continued looseness allows further short-side rebuilding — or whether the Fidelity-led institutional cluster absorbs any incremental supply.
See the live data behind this article on ORTEX.
Open TENX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
